Phase 1 Data for CITY-FXI, an RNAi Therapeutic Candidate for Thromboembolic Diseases, Selected for Oral Presentation at the 68th ASH Annual Meeting

GlobeNewswire Inc. | Nov 4, 2026 9:01 AM EST